Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

22.2%

2 terminated/withdrawn out of 9 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

44%

4 trials in Phase 3/4

Results Transparency

0 of 6 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4

4(80.0%)

N/A

1(20.0%)

5Total

Phase 4(4)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT01199692Completed

Characterization of Metabolic Biomarkers in Varying Subjects

Role: lead

NCT00960765Completed

Endotoxin and Intestinal Flora Before and After Gastric Bypass or Banding in Diabetics

Role: lead

NCT00245453Phase 4Withdrawn

Outpatient Registry Trial of Respiratory Tract Infections in Adults

Role: lead

NCT00721487Completed

Outcomes of Patients Who Fail to Respond to Fluconazole Treatment of Severe Candida Albicans Infections

Role: lead

NCT01724671Unknown

Vancomycin Versus Ceftaroline in Patients With Infections Caused by MRSA That Are Susceptible to Ceftaroline

Role: lead

NCT00419991Phase 4Completed

Open Label Non-comparative Clinical Trial of Tigecycline in Patients With Catheter Infection

Role: lead

NCT00358202Phase 4Completed

Cefepime vs. Ceftriaxone to Treat Nursing Home-Acquired Pneumonia

Role: lead

NCT00245440Phase 4Terminated

Study to Measure the Impact of Antibiotics on Bacterial Flora in Adults With Acute Sinusitis

Role: lead

NCT00245427Not ApplicableCompleted

Outcomes of Patients Not Responding to Antibiotics in the Community

Role: lead

All 9 trials loaded